Injective (INJ) is currently priced at $4.32, reflecting a significant 13.01% increase over the last 24 hours. The daily trading range has been between a low of $3.82 and a high of $4.35, indicating strong volatility and investor interest in the asset.

The trading volume stands at approximately 114.39 million, which constitutes 26.48% of the market cap, suggesting robust liquidity for INJ. The hourly moving averages indicate bullish momentum, with the 8 SMA at $4.22 showing a 2.34% increase, while longer-term averages also reflect positive gains, particularly the 144 SMA at $3.84 with a 12.59% rise.

Technical indicators such as the 1-hour RSI at 74 suggest that INJ is approaching overbought territory, which may lead to short-term corrections. However, the 7-day RSI at 59 and the strong price changes over 7 days (18.23%), 14 days (25.36%), and 30 days (49.38%) indicate a sustained upward trend in the medium term.

Injective's all-time high of $52.62, achieved in March 2024, provides a significant upside potential, yet it also underscores the volatility risks associated with such high valuations. Investors should note the recent strong performance but remain cautious of potential corrections given the overbought signals in the short term.

In conclusion, the current bullish trend, coupled with solid volume and positive moving averages, supports a Buy rating for Injective (INJ). However, investors should be prepared for possible short-term pullbacks and manage risk accordingly.